ArticleBreast cancer (Tokyo, Japan)2026
Is there an impact of autoimmune rheumatological diseases on cutaneous toxicity in breast cancer adjuvant radiotherapy? A mono-institutional experience.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAutoimmune rheumatological diseases (ARDs) have historically represented an absolute or relative contraindication for radiotherapy (RT) due to increased RT-related toxicity and the potential exacerbation of rheumatologic disease. ARDs are more frequent in females (F:M 4:1). Breast cancer (BC) is the most common malignancy, accounting alone for 31% of female cancers. This study compared acute and late cutaneous toxicity in ARDs and non-ARDs population undergoing adjuvant breast RT.
methodsData of patients with BC and ARDs treated between 2013 and 2023 were retrospectively reviewed. The ARDs group was compared with a control group in a 1:2 ratio, homogeneous by age, type of treatment, RT total doses and fractionations, and target volumes' prescription. Acute and late toxicity were recorded using RTOG scales.
resultsWe included 44 women with ARDs (median age 61 years) and 88 woman (median age 62 years) as control group. In ARDs group, the most used RT schedules were conventional fractionation (72.7%), while hypofractionation schedule (40-44 Gy) was administered in 12 patients (27.3%). In the control group, 64 patients (72.7%) received RT with conventional fractionation and 24 patients (27.3%) hypofractionation (40-44 Gy). Overall acute skin toxicity rate was 80.4% in the control group vs 86.4% in the ARDs group (p = 0.681). Specifically, G2 toxicity was 22.0% in the control group vs 31% in the ARDs group, while G3 acute toxicity was 2.3% in both groups. Overall late skin toxicity was 21.6% in the control group vs 27.3% in ARDs group (p = 0.067). Statistically significant difference was observed in late G2 toxicity with a 0% rate in the control group vs 6.8% in the experimental group (p = 0.035), respectively.
conclusionsARDs do not seem to represent an absolute or relative contraindication in BC RT in terms of acute and late cutaneous toxicity. Hypofractionated schedule showed less toxicities in both group and, particularly, in ARDs group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.